Vifor Pharma
Mr. Alexandros Sigalas (Acting CFO & Head of IT & Admin.)
Mr. Frederic Zwahlen (Head of Technical Operations)
Mr. Julien Vignot (Head of Investor Relations & Treasury)
Summary
History
In 1872, Caspar Friedrich Hausmann founds a pharmacy in St. Gallen
In 1927, 16 pharmacists establish a joint purchasing centre, Collaboration Pharmaceutique SA, which went on to be renamed Galenica AG in 1933
In 1944, The pharmacist René Grosclaude founds Vifor Ltd; the company produces over-the-counter medicines
In 1983, Hausmann AG laboratories is acquired by Galenica
In 1991, Vifor Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products
In 2008, Vifor Pharma is founded following the $915 million acquisition of a Canadian company, Aspreva Pharmaceutical Corporation, Vifor Ltd. and Vifor Ltd. are integrated in Vifor Pharma.
In 2009, Galenica acquires OM Pharma, a Swiss biotechnology company
In 2010, Vifor Pharma Group and Fresenius Medical Care found the joint company Vifor Fresenius Medical Care Renal Pharma
In 2014, Galenica is divided into two divisions, Vifor Pharma and Galenica Santé
In 2016, Relypsa, a US based biotechnology company, is purchased for $1.53 billion
In 2017, the IPO of Galenica Santé is completed and listed on the Swiss Stock Exchange. Galenica AG and Vifor Pharma AG are listed as independent entities since
In 2018, the US Food and Drug Administration FDA approved a Supplemental New Drug Application for the potassium binder Veltassa with or without food
In 2019, Vifor Fresenius Medical Care Renal Pharma received the Swiss Success Award from the non-profit organisation Swiss Biotech Association
In 2020, Vifor Pharma sells 100% of OM Pharma to Optimus Holding Limited for CHF 435 million
In 2020, Vifor Pharma also forms a Joint Venture agreement with Fresenius Kabi for the market in the People's Republic of China in the area of intravenous iron deficiency treatments
In the same year, a deal with Cara Therapeutics for the commercialisation of Difelikefalin to treat CKD-aP patients has been signed.
In 2021 Vifor Pharma concluded a licensing agreement for the commercialisation of sparsentan in Europe, Australia, and New Zealand.
In the same year, Tavneos was approved in the US, Japan and the EU. Korsuva / Kapruvia reached approval in the United States and the EU.
In November 2021, Vifor Pharma Group acquired Sanifit with its novel inhibitor of vascular calcification SNF472 for the treatment of calcific uremic arteriolopathy and peripheral artery disease in patients with end-stage kidney disease. On the same day, Vifor announced the acquisition of Swiss-based Inositec who develops treatments for soft tissue and vascular calcification disorders and aortic valve stenosis .
In December 2021 CSL Limited announced it would acquire Vifor Pharma for CHF 10.9 billion . The capital raising is considered one of the ten largest secondary-market deals worldwide in 2021.
In August 2022 the acquisition of Vifor Pharma by Australian company CSL was completed. Vifor Pharma became CSL Vifor.
Mission
Vision
Key Team
Dr. Oliver P. Kronenberg (Group Gen. Counsel)
Ms. Nathalie Ponnier (Global Head Corp. Communications)
Mr. Michael Puri (Chief HR Officer)
Dr. Christoph Springer (Chief Strategy Officer)
Dr. Thomas Kaspar (Head of Global Quality Management)
Dr. Thierry Teil (Head of Global Medical Affairs)
Ms. Carolina Ponchione (Head of Exec. Search & Employer Branding)
Recognition and Awards
References
Mr. Alexandros Sigalas (Acting CFO & Head of IT & Admin.)
Mr. Frederic Zwahlen (Head of Technical Operations)
Mr. Julien Vignot (Head of Investor Relations & Treasury)
